[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100113834":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":11,"locations":31,"responsibleParty":44,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"healthy volunteers","EXPERIMENTAL",null,[13],"Drug: PF-3864086",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","PF-3864086","The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.",[9],{"type":21,"name":15,"description":15,"armGroupLabels":26,"otherNames":11},[15],[28],{"name":29,"affiliation":5,"role":30},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[32],{"facility":33,"status":11,"city":34,"state":11,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":11},"Pfizer Investigational Site","Brussels","1070","Belgium","BE",{"type":39,"coordinates":40},"Point",[41,42],4.34878,50.85045,{"lat":42,"lon":41},{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":45,"oldOrganization":46},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100113834","phase-1-a-study-to-investigate-the-safety-toleration-and-pharmacokinetics-of-single-oral-doses-of-pf-03864086-in-healthy-male-subjects-100113834",false,"NCT00747058","A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects","A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects","Inclusion Criteria:\n\n* healthy male volunteers\n* no drug history\n* no other medication for 28 pre-dose\n\nExclusion Criteria:\n\n* age below 21 years\n* age above 55 years",true,"MALE","21 Years","55 Years",{"count":59,"type":60},28,"ACTUAL","INTERVENTIONAL",[63],"PHASE1","The purpose of this study is to determine the safety and tolerability of PF-03864086 in healthy male human volunteers. Determine the pharmacokinetics (calculations of the rate of elimination of PF-03864086 from the body once the compound is ingested).",[66],"Pain",[68],"phase 1, human study, healthy volunteers","COMPLETED","2010-01-07",{"date":72,"type":73},"2010-01-08","ESTIMATED",{"date":75,"type":11},"2008-08",{"date":77,"type":60},"2008-12",{"name":5,"class":6},1]